Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Similar articles for PubMed (Select 23640602)

1.

A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice.

Wang X, Lu XL, Zhao HY, Zhang FC, Jiang XB.

Cancer Immunol Immunother. 2013 Jul;62(7):1261-72. doi: 10.1007/s00262-013-1426-6. Epub 2013 May 3.

PMID:
23640602
2.

Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model.

Wang X, Zhang FC, Zhao HY, Lu XL, Sun Y, Xiong ZY, Jiang XB.

Tumour Biol. 2014 Aug;35(8):7781-91. doi: 10.1007/s13277-014-1867-3. Epub 2014 May 10.

3.

Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.

Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY.

J Hematol Oncol. 2013 May 9;6:33. doi: 10.1186/1756-8722-6-33.

4.

A novel fusion protein of IP10-scFv retains antibody specificity and chemokine function.

Guo JQ, Chen L, Ai HW, Jing JN, Zhou JY, Zhang CY, You SY.

Biochem Biophys Res Commun. 2004 Jul 23;320(2):506-13.

PMID:
15219858
5.

Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma.

Jiang XB, Lu XL, Hu P, Liu RE.

Vaccine. 2009 Oct 19;27(44):6210-6. doi: 10.1016/j.vaccine.2009.08.002. Epub 2009 Aug 20.

PMID:
19699331
6.

Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.

Ciesielski MJ, Kazim AL, Barth RF, Fenstermaker RA.

Cancer Immunol Immunother. 2005 Feb;54(2):107-19. Epub 2004 Aug 31.

PMID:
15340764
7.

Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.

Ohno M, Natsume A, Ichiro Iwami K, Iwamizu H, Noritake K, Ito D, Toi Y, Ito M, Motomura K, Yoshida J, Yoshikawa K, Wakabayashi T.

Cancer Sci. 2010 Dec;101(12):2518-24. doi: 10.1111/j.1349-7006.2010.01734.x. Epub 2010 Sep 30.

PMID:
20880333
8.

Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.

Ueda R, Fujita M, Zhu X, Sasaki K, Kastenhuber ER, Kohanbash G, McDonald HA, Harper J, Lonning S, Okada H.

Clin Cancer Res. 2009 Nov 1;15(21):6551-9. doi: 10.1158/1078-0432.CCR-09-1067. Epub 2009 Oct 27.

9.

Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo.

Novak H, Noy R, Oved K, Segal D, Wels WS, Reiter Y.

Int J Cancer. 2007 Jan 15;120(2):329-36.

PMID:
17066453
10.

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.

Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA.

Hum Gene Ther. 2012 Oct;23(10):1043-53. doi: 10.1089/hum.2012.041. Epub 2012 Sep 24.

11.

Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.

Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H.

Gene Ther. 2004 Nov;11(21):1551-8.

PMID:
15343358
12.

Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor.

Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T, Yoshida J.

Cancer Immunol Immunother. 2001 Nov;50(9):463-8.

PMID:
11761440
13.

125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.

Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, Pastan I, Zalutsky MR, Bigner DD.

Clin Cancer Res. 1999 Jun;5(6):1539-49.

14.

Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas.

Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK, Chen W, Low WC.

J Neurooncol. 2006 Jan;76(1):23-30.

PMID:
16155724
15.

Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.

Yamanaka R, Honma J, Tsuchiya N, Yajima N, Kobayashi T, Tanaka R.

J Neurooncol. 2005 Apr;72(2):107-13.

PMID:
15925989
16.

In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.

Zhou X, Qiu J, Wang Z, Huang N, Li X, Li Q, Zhang Y, Zhao C, Luo C, Zhang N, Teng X, Chen Z, Liu X, Yu X, Wu W, Wei YQ, Li J.

J Cancer Res Clin Oncol. 2012 Jul;138(7):1081-90. doi: 10.1007/s00432-012-1181-7. Epub 2012 Mar 7.

PMID:
22392077
17.
18.

Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.

Zhang T, Sentman CL.

Cancer Res. 2011 Mar 15;71(6):2066-76. doi: 10.1158/0008-5472.CAN-10-3200. Epub 2011 Jan 31.

19.
20.

Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.

Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW, Nierkens S, Adema GJ.

Int J Cancer. 2008 Apr 15;122(8):1794-802.

PMID:
18076066
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk